COCP Margin resik Cocrystal Pharma Inc

Logo grafis cocrystalpharma.com (COCP)

Cocrystal Pharma, Inc. (COCP) leads in bioengineering through its crystallography platform for developing small molecules against COVID-19 and influenza. Tracking the revenue profitability margin on GURU.Markets, we note that the current value is -2605.30. Business stability is based on US laboratories, while long-term growth is driven by Phase 2 trials, with current R&D expenses already priced in.

COCP: Margin resik Cocrystal Pharma, Inc. 04.07.2022 - 19.11.2026

Cocrystal - rincian analitis lan metrik utama (COCP)

- rega saham lan prakiraan rega para ahli:
Analisis wiwitan perusahaan:Cocrystal Pharma, Inc.
Produk dadi Cocrystal Pharma Inc

The development of small molecules based on crystallography defines the financial profile of Cocrystal Pharma, Inc. (COCP). Net profit margin is calculated as the ratio of net income to total revenue, measuring the efficiency of monetizing each unit of revenue. Investors use this ratio to assess operational resilience and the potential of licensing deals. An increase in this metric signals business scaling, while a decline indicates rising costs. Analysis of the net profit margin allows for the timely identification of fundamental reversals.